These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29978366)

  • 1. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
    Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
    Magge D; Zenati MS; Austin F; Mavanur A; Sathaiah M; Ramalingam L; Jones H; Zureikat AH; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
    Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
    Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
    Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
    Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.
    Vogin G; Hettal L; Vignaud JM; Dartigues P; Goere D; Ferron G; Heyd B; Bereder JM; Tuech JJ; Glehen O; de Chaisemartin C; Lherm Y; Villeneuve L; Kepenekian V; Marchal F;
    Ann Surg Oncol; 2019 Mar; 26(3):852-860. PubMed ID: 30635798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.